Clinical trial · Observational
Symptoms and Clinical Signs of Hypogonadism in Testicular Cancer Survivors
NCT02240966CI-TRIAL-00023088completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to investigate the prevalence of signs and symptoms of hypogonadism in three groups of testicular cancer survivors.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cardio-vascular Disease | — | UNRESOLVED | — |
| Hypogonadism | — | UNRESOLVED | — |
| Metabolic Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Prevalence of Metabolic Syndrome in the three groups of testicular cancer survivors according to International Diabetes Federation Guidelines and US National Cholesterol Education Program Adult Treatment Panel III criteria
- timeFrame
- Up to 12 months
Secondary outcomes (11)
- measure
- Lean body mass (Kilogram)
- timeFrame
- Up to 12 months
- description
- Lean body mass assessed by DXA-scan
- measure
- Bone Mineral Density (Gram/cm2)
- timeFrame
- Up to 12 months
- description
- Bone mineral density assessed by DXA-scan
- measure
- Pulmonary Function: Total lung capacity, Forced vital capacity, FEV1, Diffusing capacity or of the lung for carbon monoxide
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Earlier treatment of testicular germ cell cancer * No sign of relapse \> 1 year since latest treatment * Testosterone \< 12 nmol/L and luteinizing hormone \> 8 IE/L OR * Testosterone \> 12 nmol/L and LH \> 8 IE/L OR * Testosterone and LH within their normal ranges Exclusion Criteria: * Testosterone substitution
References
Publications (2)
- DERIVEDBandak M, Jorgensen N, Juul A, Lauritsen J, Oturai PS, Mortensen J, Hojman P, Helge JW, Daugaard G. Leydig cell dysfunction, systemic inflammation and metabolic syndrome in long-term testicular cancer survivors. Eur J Cancer. 2017 Oct;84:9-17. doi: 10.1016/j.ejca.2017.07.006. Epub 2017 Jul 31. PMID 28772110
- DERIVEDBandak M, Jorgensen N, Juul A, Lauritsen J, Kier MGG, Mortensen MS, Oturai PS, Mortensen J, Hojman P, Helge JW, Daugaard G. Reproductive hormones and metabolic syndrome in 24 testicular cancer survivors and their biological brothers. Andrology. 2017 Jul;5(4):718-724. doi: 10.1111/andr.12355. Epub 2017 Jun 9. PMID 28598554